Enzymatic activity evaluation of novel adenosine derivatives as Abl kinase inhibitors
Enzymatic activity evaluation of novel adenosine derivatives as Abl kinase inhibitors
Jorge Victor M. Cordeiro (IC)a, Fernando Fumagalli (PQ)b, Flávio da Silva Emery (PQ)b, Heberth de Paulaa (PQ), Pedro A. B. Moraisa (PQ)
Federal University of Espírito Santo
a Chemistry and Physics Department, CCENS, Campus Alegre, ES, Brazil
b School of Pharmaceutical Sciences of Ribeirão Preto
Introduction. The treatment of Chronic myeloid leukemia (CML) has advanced considerably in recent years and molecular therapy with tyrosine kinase inhibitors dramatically changed the traditional therapy, demonstrating promising results for patients with CML (1). A potential role for certain protein kinases, such as Abl kinase, in tumorigenesis is evidenced by ability to transform normal cells into neoplastic phenotypes when expressed in mutated and unregulated forms or at abnormally high levels (2). AIM. In this work is described enzymatic activity evaluation against Abl kinase with 3 novel adenosine derivatives. Methods. Enzymatic Activity. Abl kinase inhibition activity was measured via a ADP-Glo™ Kinase Assay that quantifies the kinase-dependent enzymatic production of ADP from ATP using a coupled luminescence-based reaction. ABL Tyrosine kinase enzyme (100ηg/µL) was diluted by 40 times with 1x buffer solution (8mM Tris, pH 7.5; 4mM MgCl2; 0.02mg/mL BSA; 10µM DTT). A substrate mix solution was prepared by adding: Abltide synthetic peptide substrate (YRRAAVPPSPSLSRHSSPHQ(pS)EDEEE) 50%; 4x buffer solution, 25% and ATP 100µM 25%. The reaction was made by adding 5µL of the inhibitor compound or distilled water (control) and 20µL of enzyme solution and incubated at 30°C for 10min. After, 20µL substrate mix solution was added and incubated at 30°C for 15min. All the ATP non-transformed by enzyme was depleted by adding 50 µL ADP-GLO® reagent during 40 min at room temperature. The ADP enzyme-produced reacted with 100µL ADP-GLO Detection Reagent® during 60min and the luminescence recorded (integration time 0.5-1s). The control tube was assumed as 100% enzymatic activity. All reagents were purchased from Promega, LLC.
Figura 1. Triazolic derivatives of adenosine.
Results. 3 inhibitors candidates were tested at 100µM concentration (Figure 1). All compounds inhibited more than 50% of the Abl kinase enzymatic activity: T8 (50.46%), T9 (57.41%) and T10 (51.36%) (Table 1).
Table 1. Abl kinase inhibition activity of the adenosine derivatives T8-10
Comp. no % Yield % Abl kinase inhibition at 100µM
T8 20 50,46
T9 20 57,41
T10 10 51,36
Conclusion. Results showed that these novels adenosine triazolic derivatives are promisor as Abl kinase inhibitors. Further investigations are ongoing in order to obtain IC50 value of these interesting Abl kinase inhibitors. References. 1. Lopes NR, Abreu M. Inibidores de tirosino quinase na leucemia mielóide crônica. Rev Bras Hematol Hemoter. 2009;31(6):449-53. 2. Fry DW, Nelson JM, Slintak V, Keller PR, Rewcastle GW, Denny WA, et al. Biochemical and antiproliferative properties of 4-[ar (alk) ylamino] pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochemical pharmacology. 1997;54(8):877-87. Keywords. Abl kinase activity, Medicinal Chemistry, Drug Discovery. Acknowledgments. This work was supported by FAPES and UFES.